Treatment with Omalizumab in adults with severe allergic reduces Fc?I expression on dendritic cells and improves antiviral responses

Conclusion: Adults with severe allergic asthma demonstrate impaired systemic DC immune responses to IAV and RV. Treatment with Omalizumab, that results in reduced exacerbations is associated with reduced DC FcI expression, enhanced DC IFN-α/ responses to viruses and this effect is seen within 4 weeks treatment.

Source: European Respiratory Journal - November 20, 2019 Category: Respiratory Medicine Authors: Wark, P., Nichol, K., Dorahy, D., Collison, A., Mattes, J. Tags: Allergy and immunology Source Type: research